Recent Updates — CMND
Clearmind Medicine Inc. announced the completion of patient recruitment for Part B of its ongoing Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe Alcohol Use Disorder (AUD). This segment marks the company's first clinical evaluation of the drug in AUD patients, following the successful completion of Part A in healthy volunteers. The trial involves two sequential single-dose ascending cohorts of six patients each, assessing safety, tolerability, pharmacokinetics, and early efficacy signals. Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric and addiction disorders.
On October 16, 2026, Clearmind Medicine Inc. delivered notice to the CLA Investors to issue and sell convertible promissory notes with an aggregate principal amount of $2,000,000. The company will receive an aggregate purchase price of $1,800,000 in cash, representing 90% of the principal amount. The transaction is expected to close on or before October 19, 2026. This issuance is part of a broader amendment dated April 30, 2026, which authorized the sale of up to $10,000,000 in convertible promissory notes under existing securities purchase agreements. Clearmind Medicine Inc. operates in the biotechnology industry, focusing on the development of novel therapeutics for neurological and psychiatric disorders.
Clearmind Medicine Inc. announced a reverse stock split of its common shares at a ratio of 1-for-8, consolidating eight pre-split shares into one post-split share. The transaction will reduce the number of issued and outstanding ordinary shares from 4,059,227 to approximately 507,404, with no fractional shares issued; any fractions are rounded up to the nearest whole share. Proportionate adjustments apply to the exercise prices and share counts of all outstanding options and warrants. The new CUSIP number is 185053709, and trading on the Nasdaq Capital Market under the split terms begins on October 5, 2026. Clearmind Medicine Inc. operates in the biotechnology industry, focusing on the development of psychedelic-based therapeutics for mental health disorders.